Literature DB >> 7624896

Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels.

K Morita1, A Yamaji.   

Abstract

The relationship between albumin or alpha 1-acid glycoprotein (AAG) levels and vancomycin (VCM) protein binding was studied in 44 serum samples from the 10 patients with methicillin-resistant Staphylococcus aureus (MRSA) infection receiving VCM therapy. Eighty serum samples from 80 healthy subjects were used as a control for albumin and AAG levels. The protein binding percentage of VCM in the serum of the patients varied widely from 27 to 62%. The mean albumin level (34 g/L) was significantly lower than that in healthy subjects (46 g/L). There was no correlation between the binding percentage and serum albumin level in the patients (r = -0.25, p > 0.1). The mean AAG level in the patients (1.51 g/L) was significantly higher than in healthy subjects (0.59 g/L). There was a significant correlation between the binding percentage of VCM and serum AAG level (r = 0.63, p < 0.001). The binding percentage of VCM individual patients changed in parallel to serum AAG and C-reactive protein (CRP) levels, which is a useful marker of acute phase response. There were also significant correlations between AAG, albumin, and CRP levels. The present results indicate that the increased AAG level in serum of the patients appeared to have a significant effect on the protein-binding characteristics of VCM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624896     DOI: 10.1097/00007691-199504000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2010-06-23       Impact factor: 5.790

Review 2.  Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.

Authors:  M H Kollef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

3.  Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Kingsley Coulthard; Robert W Milne; Craig R Rayner; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

4.  Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.

Authors:  Phillip J Bergen; Jurgen B Bulitta; Alan Forrest; Brian T Tsuji; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

5.  Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

Authors:  Dean Hickman; Sudthida Vasavanonda; George Nequist; Lynn Colletti; Warren M Kati; Richard Bertz; Ann Hsu; Dale J Kempf
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 6.  Colistin in the 21st century.

Authors:  Roger L Nation; Jian Li
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.